Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Diagnostics Amplicor, Cobas HCV RNA Tests To Launch By October

This article was originally published in The Gray Sheet

Executive Summary

Roche Diagnostics' Amplicor Version 2.0 and Cobas Amplicor automated Version 2.0 hepatitis C (HCV) qualitative RNA tests are expected to launch Sept. 28. The firm announced FDA approval of the tests July 9.

You may also be interested in...

Roche Amplicor, Cobas HCV RNA Tests Approvable With Conditions - Panel

Roche Molecular Systems should include in labeling for the Amplicor Version 2.0 and Cobas Amplicor automated Version 2.0 hepatitis C tests a warning that heparin use could lead to an "HCV not-detected" result, FDA's Microbiology Devices Panel agreed in recommending FDA approval at a July 28 meeting.

State Agencies Sharpen Supplement Market Oversight During Pandemic, With Industry's Thanks

"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III.  He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.

Coronavirus Update: R&D Starts, Product Delays, Continuing Collaboration

In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments. 




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts